[Treatment of glomerulonephritis with heparin (author's transl)]. / Heparinbehandlung bei Glomerulonephritis.

32 patients with different histologically proven forms of glomerulonephritis were treated with heparin for an average of 31 days. A dosage of heparin was chosen, which allowed an increase in thrombin time to 20-40 seconds. Histological findings alone do not allow any prediction concerning the therapeutic success of heparin treatment in glomerulonephritis. According to our results and comparable information given in the literature, the following therapeutic scheme can be recommended: Best results are seen in patients with a slow decrease of GFR (i.e. less than 30 ml/min) during the year preceding the beginning of the treatment. In rapid progredient glomerulonephritis, however, as in patients without any changes of GFR during this time, predictions as to the course of illness cannot be made. A high level of fibrin split products in serum may be expected to be the most valuable sign of therapeutic effect, as could be documented in 7 out of 8 successfully treated patients. Hypertension and proteinuria were not influenced by the treatment. Because of severe side effects the heparin treatment of glomerulonephritis should not be initiated in patients with severe hypertension.

[Severe side-effects during peritoneal dialysis caused by sorbitol-containing dialysate (author's transl)]. / Sorbithaltige Spüllösung als Ursache schwerer Unverträglichkeitserscheinungen bei der Peritonealdialyse

In seven patients with chronic renal failure in an advanced stage 17 episodes of upper abdominal pain, hypertension, vomiting and (in some of them) coma occurred during peritoneal dialysis with sorbitol-containing dialysate. The signs recurred in some of the patients but did not when glucose-containing dialysate of otherwise identical composition was used. Very high levels of sorbitol in CSF and serum were measured in the comatose patients. The precipitating factor is probably a reduced metabolic breakdown of sorbitol in renal failure with preferential intracellular deposition of sorbitol and subsequent cellular oedema. To avoid this dangerous reaction it is necessary to use glucose instead of sorbitol in peritoneal dialysates, despite the technical problems of sterilisation. Where this is not possible, glucose should be added in order to reduce the sorbitol concentration in the dialysate to less than 15g/l.

Use of Tenckhoff catheter for peritoneal dialysis in terminal renal failure.

Over a period of 33 months a total of 2,146 peritoneal dialyses were carried out by means of indwelling Tenckhoff catheters in 65 patients suffering from terminal renal failure. The patients were maintained on peritoneal dialysis for periods varying from two weeks to 13 months. Treatment over long periods was possible in only a few cases. Infection and clotting, which tended to limit the functional life of the catheters, was reduced by rigid asepsis and by adding heparin to the dialysate. The Tenckhoff catheter was found to be valuable for peritoneal dialysis as a short-term measure, especially in patients in whom haemodialysis was not immediately feasible, in borderline cases when kidney function was not too seriously impaired, and as an alternative to haemodialysis when that was interrupted by complications.